Maxim Gorbachev

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Sukhoi Civil Aircraft JSC engages in the development and manufacturing of aircraft. Its activities include design and manufacturing of new models of civil aircraft, as well as certification, general project management, sales and after sales support. The company was founded on May 25, 2000 and is headquartered in Moscow, Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.